Abstract
Cultures of normal donor peripheral blood mononuclear cells were testedin vitro for suppression by chemotherapeutic agents or their metabolites. The drugs tested were those commonly used in the treatment of breast cancer, namely, 5-fluorouracil, doxorubicin, vincristine, methotrexate and cyclophosphamide (actually testing its active metabolite, 4-hydroxy-cyclophosphamide). The lymphocytes were stimulated by phytohaemagglutinin (PHA), and the inhibitory effect of the drugs on subsequent DNA synthesis was measured by tritiated thymidine uptake. Drug concentrations used were equivalent to expectedin vivo plasma and body fluid levels following i.v. injection of a standard therapeutic dose. Results suggest that the drugs may be ranked for suppression of T-cell function as follows: doxorubicin>vincristine=cyclophosphamide>5-fluorouracil>methotrexate.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
J. Harris, D. Sengar, T. Stewart and D. Hyslop,The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease, Cancer37, 1058–1069 (1976).
C. Gropp and K. Havemann,Cellular immune reactions in patients with bronchogenic carcinoma before and after radiochemo-and immunotherapy, Z. Immun. Forsch.153, 235–247 (1977).
E. Z. Ezdinli, K. L. Simonson and R. A. Smith,Comparison of the effects of single versus multiple chemotherapy on lymphocytes assayed by the rosette technique, Cancer42, 2234–2243 (1978).
A. Tovainen and E. Nordman,Effects of radiation and cytostatic treatment on the immune functions of cancer patients, Cell. Molec. Biol.26, 341–346 (1980).
L.-E. Strender, H. Blomgren, B. Petrini, J. Wasserman, M. Forsgren, R. Norberg, E. Baral and A. Wallgren.Immunologic monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy. Cancer48, 1996–2002 (1981).
I. R. Mackay, M. D. Goodyear, C. Riglar, J. Penschow, S. Whittingham, I. S. Russell, P. R. B. Kitchen and J. P. Collins,Effect on immunologic and other indices of adjuvant cytotoxic chemotherapy including melphelan in breast cancer, Cancer53, 2619–2627 (1984).
H. M. Anthony, G. H. Templeman, K. E. Madsen and M. K. Mason,The prognostic significance of DHS skin tests in patients with carcinoma of bronchus, Cancer34, 1901–1906 (1974).
S. M. Watkins,Cancer prognosis predicted by preoperative lymphocyte responsiveness in vitro, Br. J. Surg.63, 433–434, (1976).
R. Mandeville, G. Lamoureux, S. Legault-Poisson and R. Poisson,Biological markers and breast cancer. A multiparametric study. II Depressed immune competence. Cancer50, 1280–1288 (1982).
C. M. Haskell,Immunologic aspects of cancer chemotherapy, Ann. Rev. Pharmacol. Toxicol.17, 179–195 (1977).
F. Mauro, W. Göhde, J. Schumann, L. Teodori and M. Spano,Considerations in the design of possible cell cycle effective drugs Int. J. Radiat. Biol.49, 307–333 (1986).
J. C. Reed, J. D. Alpers, P. C. Nowell and R. G. Hoover,Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc. Natl. Acad. Sci. USA83, 3982–3986 (1986).
R. J. Berry, A. H. Laing and J. Wells,Fresh explant cultures of human tumours in vitro and the assessment of sensitivity to cytotoxic chemotherapy, Br. J. Cancer31, 218–227 (1975).
M. Volm, K. Wayss, M. Kaufmann and J. Mattern,Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy, Eur. J. Cancer15, 983–993 (1979).
A. E. Bateman, M. J. Peckham and G. G. Steel,Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour, Br. J. Cancer40, 81–88 (1979).
N. T. Bech-Hansen, F. Sarangi, D. J. A. Sutherland and V. Ling,Rapid assays for evaluating the drug sensitivity of tumor cells, J. Natl. Cancer Inst.59, 21–27 (1977).
B. R. Bullen, C. W. Russell and G. R. Giles,A comparison of the chemosensitivity of murine tumours in vivo and in cell culture, Clin. Oncol.4, 265–272 (1978).
M. Kaufmann, J. Mattern, M. Volm, H. J. Hohorst, G. Peter and G. Voelcker,In vitro testing of cyclophosphamide on tumours, Naturwissenschaften62, 446–447 (1975).
E. Piazza, M. G. Donelli, M. Broggini, C. Sessa, N. Natale, L. Ottolenghi, S. Marsoni, A. Libretti, C. Mangioni and L. Morasca,Early phase pharmacokinetics of doxorubicin (Adriamycin) in plasma of cancer patients during single- or multiple-drug therapy, Cancer Treat. Rep.64, 845–854 (1980).
R. E. Finch, M. R. Bending and A. F. Lant,Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients, Br. J. Clin. Pharmac.7, 613–617 (1979).
E. S. Henderson, R. H. Adamson and V. T. Oliverio,The metabolic fate of tritiated methotrexate. II Absorption and excretion in man, Cancer Res.25, 1018–1024 (1965).
R. A. Bender, M. C. Castle, D. A. Margileth and V. T. Oliverio,The pharmacokinetics of [ 3 H]-vincristine in man, Clin. Pharmacol. Ther.22, 430–438 (1977).
G. Voelcker, T. Wagner, C. Wientzek and H.-J. Hohorst,Pharmacokinetics of “activated” cyclophosphamide and therapeutic efficacies, Cancer54, 1179–1186 (1984).
J. Y. Jao, W. J. Jusko and J. L. Cohen,Phenobarbital effects on cyclophosphamide pharmacokinetics in man, Cancer Res.32, 2761–2764 (1972).
G. M. L. Gyte and S. M. Watkins,Lymphocyte transformation in cancer patients: variation of results according to technique, J. Clin. Path.31, 125–128 (1978).
J. H. Gibbs, R. A. Brown, A. J. Robertson, R. C. Potts and J. Swanson Beck,A new method of testing for mitogen-induced lymphocyte stimulation: measurement of the percentage of growing cells and of some aspects of their cell kinetics with an electronic particle counter, J. Immunol. Methods25, 147–158 (1979).
A. P. Burford-Mason and G. M. L. Gyte,An alternative method of expressing results of lymphocyte transformation experiments, J. Immunol. Methods28, 391–394 (1979).
I. E. Smith,Controversies in the medical management of breast cancer, Postgrad. Med. J.61, 117–122 (1985).
K. W. Brunner, T. Marthaler and W. Müller,Unfavourable effects of long-term adjuvant chemotherapy with Endoxan in radically operated bronchogenic carcinoma, Europ. J. Cancer7, 285–294 (1971).
J. V. Moore and B. Dixon,Metastasis of a transplantable mammary tumour in rats treated with cyclophophamide and/or irradiation, Br. J. Cancer36, 221–226 (1977).
M. H. Amer,Chemotherapy and pattern of metastases in breast cancer patients, J. Surg. Oncol.19, 101–105 (1982).
T. Makinoden, G. W. Santos and R. P. Quinn,Immunosuppressive drugs, Pharmacol. Rev.22, 189–247 (1970).
B. T. Hill and R. Baserga,The cell cycle and its significances for cancer treatment, Cancer Treat. Rev.2(3), 159–75, (1975).
J. L. Weese, R. K. Oldham, D. C. Tormey, A. L. Barlock, A. Morales, M. H. Cohen, W. H. West, R. B. Herberman, T. C. Alford, P. E. Shorb, N. T. Tsangaris, G. B. Cannon, J. H. Dean, J. Djen and J. L. McCoy,Immunologic monitoring in carcinoma of the breast, Surg. Gynecol. Obstet.145, 209–218 (1977).
S. I. Sergejew, W. W. Gorodilowa, A. P. Baschenowa, E. W. Mandrik and I. W. Kasjanow,Immunreaktionen bei Mammacarzinompatientinnen, Arch. Geschwulstforsch.47, 421–427 (1977).
J. Zighelboim, F. Dorey, N. H. Parker, T. Calcaterra, P. Ward and J. L. Fahey,Immunologic evaluation of patients with advanced head and neck cancer receiving weekly chemoimmunotherapy, Cancer44, 117–123 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gereis, M., Burford-Mason, A.P. & Watkins, S.M. Suppression ofin vitro peripheral blood lymphocyte mitogenesis by cytotoxic drugs commonly used in the treatment of breast cancer: A comparative study. Agents and Actions 22, 324–329 (1987). https://doi.org/10.1007/BF02009063
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02009063